Study identifier:NIS-ORU-XXX-2014/2
ClinicalTrials.gov identifier:NCT02155998
EudraCT identifier:N/A
CTIS identifier:N/A
A Non-interventional Study of Postoperative or post-Radiation trEatment habits in locally adVanced prostate cancer patiENTs (high risk)- PREVENT
postoperative or postradiation adjuvant androgen deprivation therapy in locally advanced prostate cancer (high and very high risk) patients
N/A
No
-
Male
200
Observational
N/A
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Apr 2019 by AstraZeneca
AstraZeneca
-
This is a multicentre, non-interventional, prospective study to be carried out in representative medical institutions in order to get the information on administration of postoperative and post-radiation adjuvant androgen deprivation therapy (including “go” / “no go” decision, regimens, dosages and duration) used in locally advanced prostate cancer patients with high and very high risk of recurrence in Russia.
This is a multicentre, non-interventional, prospective study to be carried out in representative medical institutions in order to get the information on administration of postoperative and post-radiation adjuvant androgen deprivation therapy (including “go” / “no go” decision, regimens, dosages and duration) used in locally advanced prostate cancer patients with high and very high risk of recurrence in Russia. No additional procedures besides those already used in the routine clinical practice will be applied to the patients. Treatment assignment will be done according to the current practice. It is planned to enrol 200 subjects in up to 30 sites in Russian Federation. The average number of patients per site is planned as 6 - 10; there are no restrictions on minimum and maximum number of subjects per site in this study.
Location
Location
Moscow, Russian Federation
Location
Balashikha, Russian Federation
Location
St.Petersburg, Russian Federation
Location
Rostov-on-Don, Russian Federation
Location
Novosibirsk, Russian Federation
Location
Tumen, Russian Federation
Location
Perm, Russian Federation
Location
Belgorod, Russian Federation
Arms | Assigned Interventions |
---|---|
PREVENT study patients Patients with locally advanced prostate cancer with high and very high risk of recurrence, who underwent surgery or radiotherapy within 3 months prior to enrolment, 18 years and older, consented to participate in this non-interventional study, being treated for prostate cancer in the oncology institutions / departments in the Russian Federation. | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.